188 related articles for article (PubMed ID: 35950390)
1. [Optimal surveillance intensity of cystoscopy in intermediate-risk non-muscle invasive bladder cancer].
Wang F; Qin CP; DU YQ; Liu SJ; Li Q; Xu T
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):669-673. PubMed ID: 35950390
[TBL] [Abstract][Full Text] [Related]
2. Surveillance Intensity in Intermediate Risk, Nonmuscle Invasive Bladder Cancer: Revisiting the Optimal Timing and Frequency of Cystoscopy.
Bhat A; Kwon D; Soodana-Prakash N; Mouzannar A; Punnen S; Gonzalgo ML; Parekh DJ; Ritch CR
J Urol; 2021 Jul; 206(1):22-28. PubMed ID: 33617331
[TBL] [Abstract][Full Text] [Related]
3. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
4. The impact of low- versus high-intensity surveillance cystoscopy on surgical care and cancer outcomes in patients with high-risk non-muscle-invasive bladder cancer (NMIBC).
Rezaee ME; Lynch KE; Li Z; MacKenzie TA; Seigne JD; Robertson DJ; Sirovich B; Goodney PP; Schroeck FR
PLoS One; 2020; 15(3):e0230417. PubMed ID: 32203532
[TBL] [Abstract][Full Text] [Related]
5. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
[TBL] [Abstract][Full Text] [Related]
6. The impact of frequent cystoscopy on surgical care and cancer outcomes among patients with low-risk, non-muscle-invasive bladder cancer.
Schroeck FR; Lynch KE; Li Z; MacKenzie TA; Han DS; Seigne JD; Robertson DJ; Sirovich B; Goodney PP
Cancer; 2019 Sep; 125(18):3147-3154. PubMed ID: 31120559
[TBL] [Abstract][Full Text] [Related]
7. Ta T1 low and intermediate transitional cell carcinoma of the bladder: recurrence rates and the timing of check cystoscopies within the first year.
Guney S; Guney N; Canogullari Z; Ergenekon E
Urol Int; 2008; 80(2):124-8. PubMed ID: 18362479
[TBL] [Abstract][Full Text] [Related]
8. Optimal timing for the first cystoscopic follow-up using time-to-treatment initiation analysis of oncologic outcomes in primary non-muscle invasive bladder cancer.
Kim JS; Lee J; Nguyen TT; Choi SY
Sci Rep; 2024 Apr; 14(1):8440. PubMed ID: 38600160
[TBL] [Abstract][Full Text] [Related]
9. Utilising alternative cystoscopic schedules to minimise cost and patient burden after trimodality therapy for muscle-invasive bladder cancer.
Krishnatry R; Maitre P; Kumar A; Telkhade T; Bakshi G; Prakash G; Pal M; Joshi A; Menon S; Murthy V
Cancer Med; 2023 May; 12(10):11305-11314. PubMed ID: 36965102
[TBL] [Abstract][Full Text] [Related]
10. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P
BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438
[TBL] [Abstract][Full Text] [Related]
11. Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non-Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013.
Bree KK; Shan Y; Hensley PJ; Lobo N; Hu C; Tyler DS; Chamie K; Kamat AM; Williams SB
JAMA Netw Open; 2022 Mar; 5(3):e223050. PubMed ID: 35302627
[TBL] [Abstract][Full Text] [Related]
12. Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non-muscle-invasive bladder cancer and with low and intermediate EORTC-risk score.
Simon M; Bosset PO; Rouanne M; Benhamou S; Radulescu C; Molinié V; Neuzillet Y; Paoletti X; Lebret T
PLoS One; 2019; 14(2):e0211721. PubMed ID: 30811419
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Prospective Outcomes of Patients with Non-Muscle Invasive Bladder Cancer After Holmium Laser Ablation.
Darrad M; Jah S; Ahmed Z; Syed H
J Endourol; 2019 Nov; 33(11):938-945. PubMed ID: 31432709
[No Abstract] [Full Text] [Related]
14. Long-term Recurrence Rates of Low-risk Non-muscle-invasive Bladder Cancer-How Long Is Cystoscopic Surveillance Necessary?
Ma J; Roumiguie M; Hayashi T; Kohada Y; Zlotta AR; Lévy S; Matsumoto T; Sano T; Black PC
Eur Urol Focus; 2024 Jan; 10(1):189-196. PubMed ID: 37442722
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of the intensity of follow-up cystoscopy in patients with high-risk non-muscle-invasive bladder cancer.
Miyake M; Nishimura N; Nishioka Y; Fujii T; Oda Y; Miyamoto T; Tomizawa M; Shimizu T; Owari T; Ohnishi K; Hori S; Morizawa Y; Gotoh D; Nakai Y; Torimoto K; Tanaka N; Imamura T; Fujimoto K
Int Urol Nephrol; 2024 Mar; 56(3):827-837. PubMed ID: 37910382
[TBL] [Abstract][Full Text] [Related]
16. The role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancer.
Karaoglu I; van der Heijden AG; Witjes JA
World J Urol; 2014 Jun; 32(3):651-9. PubMed ID: 24166285
[TBL] [Abstract][Full Text] [Related]
17. Management of high-risk non-muscle invasive bladder cancer.
Brausi M; Olaru V
Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
[TBL] [Abstract][Full Text] [Related]
18. Prospective evaluation of blue-light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer.
Lotan Y; Chaplin I; Ahmadi H; Meng X; Roberts S; Ladi-Seyedian S; Bagrodia A; Margulis V; Woldu S; Daneshmand S
BJU Int; 2021 Jan; 127(1):108-113. PubMed ID: 32648957
[TBL] [Abstract][Full Text] [Related]
19. Long term follow-up in patients with initially diagnosed low grade Ta non-muscle invasive bladder tumors: tumor recurrence and worsening progression.
Kobayashi H; Kikuchi E; Mikami S; Maeda T; Tanaka N; Miyajima A; Nakagawa K; Oya M
BMC Urol; 2014 Jan; 14():5. PubMed ID: 24400640
[TBL] [Abstract][Full Text] [Related]
20. Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression.
Holmang S; Johansson SL
J Urol; 2002 Apr; 167(4):1634-7. PubMed ID: 11912378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
